(002) The Effects of Vaginal Testosterone versus Placebo on Female Sexual Function: Interim Analysis of the PIVoT Trial (Prevention of Recurrent Urinary Tract Infection using Vaginal Testosterone)

Abstract Introduction Post-menopasual women experience changes in vaginal flora and atrophy that have been associated with declining estrogen levels. These to the microenvironment often lead significant genital pain discomfort during sexual intercourse. Vaginal treats thereby restoring flora, which prevents UTIs improves function post-menopausal women. While is effective, some patients contraindications or are unwilling use it. testosterone cream (VT) has shown improve atrophy, however, its effects on overall health not fully described. Objective The purpose of this study was determine if VT more effective than placebo improving index (VHI), postmenopausal recurrent UTIs. Methods This an interim analysis a randomized, double- blind placebo-controlled pilot enrolling (VHI) swab assess via DNA sequencing were collected. Patients randomized placebo. Female (FSFI) questionnaires administered at baseline, one month, nine months post treatment. Results A total 44 enrolled. Average VHI enrollment 13.66 +/− 0.4. There no difference baseline characteristics among groups. show improvement female scores both groups from baseline. In arm, improvements seen desire (2.18 2.85), lubrication (1.74 2.175), orgasm (1.64 2.5) (0.91 1.3) domains FSFI. Interestingly, all group, group reported being sexually active. terms VHI, there statistically increase 9 post-treatment (14.65 +/−4.20 17.50 4.43, p = 0.04). observed arm. Conclusions Initial data demonstrates pH after treatment VT. Improvement also Higher patient longer follow up will be valuable understanding versus Disclosure No